Meeting
2024 ASCO Annual Meeting
Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial.
Authors
Charles B. Nguyen
Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI
Charles B. Nguyen , Ulka N. Vaishampayan , Matthew T Campbell , Hans J. Hammers , Roserika Brooks , Travis Solley , Lauren Michelle Wood , Eric Jonasch , Ajjai Shivaram Alva
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT06053658
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS4612)
DOI
10.1200/JCO.2024.42.16_suppl.TPS4612
Abstract #
TPS4612
Poster Bd #
304b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).
First Author: Jesse Meir Zaretsky
Poster
2022 ASCO Annual Meeting
A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
First Author: Erkut Hasan Borazanci
Poster
2022 ASCO Genitourinary Cancers Symposium
Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
First Author: Austin Kalirai
Poster
2020 Genitourinary Cancers Symposium
Safety and efficacy of immune checkpoint inhibitors (ICI) in metastatic non-clear cell renal cell carcinoma (nccRCC): An institutional experience.
First Author: William Schwartzman